Menarini Asia-Pacific partner of Moberg Pharma AB, a Swedish pharmaceutical company, has initiated the launch of Kerasal Nail, a topical treatment used to treat nail disease, in China. Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company - includes Italy, China and eight countries in Southeast Asia. Launch activities have previously been initiated in Malaysia, Singapore and Hong Kong.
Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments
Kerasal Nail is a prescription-free, over-the-counter product sold under the names Kerasal Nail, Naloc/Nalox and Emtrix. Kerasal Nail used to treat nail disease topically. Recently it is best-selling product in its category in the US. The international launch is under way via a proprietary sales organization in the US and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia.
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally.The Menarini Group is an Italian pharmaceutical company. It was founded in Naples, Italy, in 1886.This biopharmaceutical company with a heritage of over 127 years and nearly 17,000 employees in over 100 countries.
Subscribe to PharmaTutor News Alerts by Email >>
